Yuflyma(Cf) Autoinjector (Adalimumab-Aaty) Patent Expiration, LOE Window & CMS Spending

Yuflyma(Cf) Autoinjector (Adalimumab-Aaty) by Celltrion: Biologic BLA (Purple Book Regime), 0 AB generics, $6.1M 2024 CMS Part D & Medicaid spend, and $9,865 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCelltrion
FDA Application & PathwayB761219 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$6.1M
2024 Medicare Part D Spend$5.8M
2024 Medicaid Spend$330K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($9,865 intro WAC)